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Introduction {#ajo13204-sec-0006}
============

In December 2019, the novel coronavirus SARS‐CoV‐2 first appeared in Wuhan, China, with both the virulence and transmissibility to infect on pandemic proportions. By 1 June 2020, there were more than 6 million infections worldwide and over 371 100 deaths.[^1^](#ajo13204-bib-0001){ref-type="ref"} These figures are increasing daily and crude global mortality is estimated at 3--4% by the World Health Organization.[^2^](#ajo13204-bib-0002){ref-type="ref"} Coronavirus disease 2019 (COVID‐19) characteristically presents with fever, cough and fatigue. A severe case is defined by progression to pneumonia with hypoxia, occurring in approximately 14% of infections.[^3^](#ajo13204-bib-0003){ref-type="ref"} In 5% of cases, this progresses to critical illness, with acute respiratory distress syndrome, septic shock or other systemic complications, and usually requires mechanical ventilation.[^3^](#ajo13204-bib-0003){ref-type="ref"}

The Australian Government introduced strict physical distancing measures in mid‐March; since then the rate of new infections has been steadily declining. As of 1 June 2020, there were 7204 recorded cases and 103 deaths in Australia[^4^](#ajo13204-bib-0004){ref-type="ref"} -- a mortality rate of 1.4%. While almost all Australian deaths have occurred in people aged 60 or older, the highest total number of infections exists in the 20--29‐year‐old age group[^4^](#ajo13204-bib-0004){ref-type="ref"} which overlaps with women of reproductive age. Clinical presentation in pregnancy, maternal outcomes and neonatal outcomes of COVID‐19 infection are yet to be thoroughly understood. Furthermore, the potential for SARS‐CoV‐2 vertical transmission is currently uncertain.

Other viral illnesses in pregnancy have shown disproportionately high rates of adverse maternal and perinatal outcomes. In 2010 a US study revealed that 5% of all deaths to H1N1 influenza occurred in pregnant patients, while 23% of infected pregnant women required intensive care unit (ICU) admission.[^5^](#ajo13204-bib-0005){ref-type="ref"} Seasonal influenza also poses an increased risk of preterm birth[^6^](#ajo13204-bib-0006){ref-type="ref"} and hospital admission,[^7^](#ajo13204-bib-0007){ref-type="ref"} particularly if contracted during the third trimester of pregnancy.[^8^](#ajo13204-bib-0008){ref-type="ref"} Severe acquired respiratory syndrome (SARS) exhibited a mortality rate of around 25% in pregnant women, with up to 50% of infected pregnant women requiring ICU admission.[^9^](#ajo13204-bib-0009){ref-type="ref"} In pregnancies complicated by Middle‐East respiratory syndrome (MERS), fetal death *in utero* occurred at a rate of 30% while 33% of ongoing pregnancies were delivered preterm.[^10^](#ajo13204-bib-0010){ref-type="ref"} There is no evidence of *in utero* transmission from either SARS or MERS.[^9^](#ajo13204-bib-0009){ref-type="ref"}, [^10^](#ajo13204-bib-0010){ref-type="ref"}

The aims of this review are to: (i) describe what is known about COVID‐19 clinical disease in pregnant women; (ii) discuss obstetric outcomes; (iii) describe the risk of vertical transmission; (iv) use this data to highlight management issues in the pregnant population; and (5) identify gaps in the existing knowledge.

Materials and methods {#ajo13204-sec-0007}
=====================

The EMBASE and Medline Ovid databases were searched on 18 April, 18 May and 23 May 2020 using the keywords and Boolean terms 'coronavirus OR COVID‐19 OR COVID 19 OR SARS‐CoV‐2 OR n19‐CoV' and subject headings 'pregnancy outcome' and 'pregnancy complications'. The full search strategy for both databases is listed in Data [S1](#ajo13204-sup-0001){ref-type="supplementary-material"}. A broad search of the World Health Organization 'Global literature on coronavirus disease' database was also conducted using the keywords 'pregnancy' and 'pregnant'. These platforms collectively returned 911 papers of interest. No further searches were conducted after 23 May 2020.

After removal of duplicates, 412 articles remained (Fig. [1](#ajo13204-fig-0001){ref-type="fig"}). Papers were included if they specifically referred to pregnancy and COVID‐19. Exclusion criteria were as follows: review articles, opinion pieces or guidelines, articles pertaining solely to MERS‐CoV, SARS‐CoV or other viruses, non‐peer‐reviewed papers and case reports of a single patient. In addition to the database search described, the Cochrane Library[^11^](#ajo13204-bib-0011){ref-type="ref"} was examined for reports of COVID‐19 in pregnancy that had not been identified in the original search, revealing a further eight articles.[^12^](#ajo13204-bib-0012){ref-type="ref"}, [^13^](#ajo13204-bib-0013){ref-type="ref"}, [^14^](#ajo13204-bib-0014){ref-type="ref"}, [^15^](#ajo13204-bib-0015){ref-type="ref"}, [^16^](#ajo13204-bib-0016){ref-type="ref"}, [^17^](#ajo13204-bib-0017){ref-type="ref"}, [^18^](#ajo13204-bib-0018){ref-type="ref"}, [^19^](#ajo13204-bib-0019){ref-type="ref"}

![Research article identification and selection.](AJO-9999-na-g001){#ajo13204-fig-0001}

All selected publications were either case series or cohort studies. These cohorts included cases and either non‐infected pregnant controls or infected non‐pregnant controls.

Results {#ajo13204-sec-0008}
=======

In total, 60 studies were identified. Details of included studies are listed in Table [S1](#ajo13204-sup-0001){ref-type="supplementary-material"}. The majority of papers arose from either Wuhan, China or the United States of America (US or USA), with five from Italy, three from the United Kingdom, one from Portugal and one from Iran also included. Of the Chinese studies, six were conducted at Renmin Hospital, Wuhan,[^20^](#ajo13204-bib-0020){ref-type="ref"}, [^21^](#ajo13204-bib-0021){ref-type="ref"}, [^22^](#ajo13204-bib-0022){ref-type="ref"}, [^23^](#ajo13204-bib-0023){ref-type="ref"}, [^24^](#ajo13204-bib-0024){ref-type="ref"}, [^25^](#ajo13204-bib-0025){ref-type="ref"} five at Tongji Hospital, Wuhan,[^14^](#ajo13204-bib-0014){ref-type="ref"}, [^26^](#ajo13204-bib-0026){ref-type="ref"}, [^27^](#ajo13204-bib-0027){ref-type="ref"}, [^28^](#ajo13204-bib-0028){ref-type="ref"}, [^29^](#ajo13204-bib-0029){ref-type="ref"} three at Union Hospital, Wuhan,[^30^](#ajo13204-bib-0030){ref-type="ref"}, [^31^](#ajo13204-bib-0031){ref-type="ref"}, [^32^](#ajo13204-bib-0032){ref-type="ref"} four at Maternal and Child Health Hospital, Wuhan[^33^](#ajo13204-bib-0033){ref-type="ref"}, [^34^](#ajo13204-bib-0034){ref-type="ref"}, [^35^](#ajo13204-bib-0035){ref-type="ref"}, [^36^](#ajo13204-bib-0036){ref-type="ref"} and four at Zhongnan Hospital, Wuhan.[^13^](#ajo13204-bib-0013){ref-type="ref"}, [^37^](#ajo13204-bib-0037){ref-type="ref"}, [^38^](#ajo13204-bib-0038){ref-type="ref"}, [^39^](#ajo13204-bib-0039){ref-type="ref"} Of the US studies, four were conducted at the New York Presbyterian Hospital System.[^12^](#ajo13204-bib-0012){ref-type="ref"}, [^15^](#ajo13204-bib-0015){ref-type="ref"}, [^40^](#ajo13204-bib-0040){ref-type="ref"}, [^41^](#ajo13204-bib-0041){ref-type="ref"} Admission dates overlap for participants reported in studies from the same hospital, hence it is unclear whether the same pregnant individuals have been included in multiple publications.

Overall, these 60 studies included a total of 3830 participants: 1287 SARS‐CoV‐2 positive pregnant women (confirmed by reverse transcription polymerase chain reaction (rtPCR)), 139 pregnant women who were assigned a clinical diagnosis of infection either based on computed tomography (CT) or symptomatology but rtPCR negative, 2004 negative pregnant controls and 400 SARS‐CoV‐2 rtPCR positive non‐pregnant controls. The number of participants in each study varied from two to 635. Details of these studies are listed in Table [S1](#ajo13204-sup-0001){ref-type="supplementary-material"}, including identification of patients who were confirmed by rtPCR to have SARS‐CoV‐2, as well as those suspected or negative. Unless otherwise specified, all results in this review pertain to rtPCR confirmed SARS‐CoV‐2 cases.

Clinical characteristics {#ajo13204-sec-0009}
------------------------

The clinical symptoms among pregnant women with rtPCR confirmed SARS‐CoV‐2 infection are presented in Table [1](#ajo13204-tbl-0001){ref-type="table"}. In symptomatic patients, fever was the most common sign, occurring in 10--100% of cases both at admission and postpartum. Only one study compared clinical symptoms between COVID‐19 positive pregnant and non‐pregnant groups: fever was less prevalent in pregnant than non‐pregnant patients (44% vs 100%, *P* \< 0.05), while there was no significant difference in cough, dyspnoea or fatigue incidence.[^34^](#ajo13204-bib-0034){ref-type="ref"} Six studies universally tested all pregnant women at presentation with nasopharyngeal swab: Sutton *et al.* [^12^](#ajo13204-bib-0012){ref-type="ref"}, Gagliardi *et al*.[^42^](#ajo13204-bib-0042){ref-type="ref"}, Khalil *et al*.[^43^](#ajo13204-bib-0043){ref-type="ref"}, Vintzileos *et al*.[^44^](#ajo13204-bib-0044){ref-type="ref"}, Doria *et al*.[^45^](#ajo13204-bib-0045){ref-type="ref"} and Miller *et al*.[^46^](#ajo13204-bib-0046){ref-type="ref"} These papers reported asymptomatic infection in 43.5--92% of SARS‐CoV‐2 positive patients.

###### 

Maternal symptoms.

<table><thead><tr class="header"><th>Study<a href="#ajo13204-note-0003" data-ref-type="fn">†</a></th><th>No. rtPCR SARS‐CoV‐2 positive pregnant patients</th><th>Gestation at infection (weeks<sup>+days</sup>)</th><th>Asymptomatic (%)</th><th>Fever (%)</th><th>Cough (%)</th><th>Dyspnoea (%)</th><th>Chest tightness or pain (%)</th><th>Myalgia (%)</th><th>Headache (%)</th><th>Diarrhoea (%)</th><th>Fatigue (%)</th><th>Other – %</th></tr></thead><tbody><tr class="odd"><td>Breslin <em>et al.</em> <a href="#ajo13204-bib-0015" data-ref-type="ref"><sup>15</sup></a></td><td>7</td><td>26<sup>+0</sup>–37<sup>+5</sup></td><td>28.5</td><td>28.5</td><td>43</td><td> </td><td>28.5</td><td>43</td><td>28.5</td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Breslin <em>et al.</em> <a href="#ajo13204-bib-0040" data-ref-type="ref"><sup>40</sup></a></td><td>43</td><td>32<sup>+4</sup>–38<sup>+6</sup></td><td>33</td><td>48</td><td>65</td><td>24</td><td>17</td><td>38</td><td>28</td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Sutton <em>et al.</em> <a href="#ajo13204-bib-0012" data-ref-type="ref"><sup>12</sup></a></td><td>33</td><td>3rd trimester</td><td>88</td><td><p>12 (admission)</p><p>10 (postpartum)</p></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Baergen <em>et al.</em> <a href="#ajo13204-bib-0041" data-ref-type="ref"><sup>41</sup></a></td><td>20</td><td>32<sup>+2</sup>–40<sup>+4</sup></td><td>80</td><td>10</td><td> </td><td>10</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Chen <em>et al.</em> <a href="#ajo13204-bib-0022" data-ref-type="ref"><sup>22</sup></a></td><td>17</td><td><p><em>n</em> = 14 &gt;37</p><p><em>n</em> = 3 &lt;37</p></td><td> </td><td>24</td><td>24</td><td>6</td><td> </td><td> </td><td> </td><td>6</td><td>6</td><td> </td></tr><tr class="even"><td>Fan <em>et al.</em> <a href="#ajo13204-bib-0021" data-ref-type="ref"><sup>21</sup></a></td><td>2</td><td>36<sup>+0</sup> &amp; 37<sup>+0</sup></td><td> </td><td>100</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>Nasal congestion ‐ 100</td></tr><tr class="odd"><td>Zhang <em>et al.</em> <a href="#ajo13204-bib-0020" data-ref-type="ref"><sup>20</sup></a></td><td>16</td><td>35<sup>+5</sup>–41<sup>+0</sup></td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="even"><td>Khan <em>et al.</em> <a href="#ajo13204-bib-0023" data-ref-type="ref"><sup>23</sup></a></td><td>17</td><td>35<sup>+0</sup>–41<sup>+0</sup></td><td> </td><td>18</td><td>35</td><td>12</td><td> </td><td> </td><td> </td><td>18</td><td> </td><td>Nasal congestion ‐ 12</td></tr><tr class="odd"><td>Khan <em>et al.</em> <a href="#ajo13204-bib-0024" data-ref-type="ref"><sup>24</sup></a></td><td>3</td><td><p><em>n</em> = 1 34<sup>+6</sup></p><p><em>n</em> = 1 39<sup>+1</sup></p><p><em>n</em> = 1 38<sup>+2</sup></p></td><td> </td><td>67</td><td>100</td><td> </td><td>33</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Lei <em>et al.</em> <a href="#ajo13204-bib-0025" data-ref-type="ref"><sup>25</sup></a></td><td>9</td><td><p>2nd tri: 56%</p><p>3rd tri: 44%</p></td><td> </td><td>100</td><td>78</td><td>44</td><td>33</td><td>44</td><td>33</td><td>56</td><td>44</td><td> </td></tr><tr class="odd"><td>Chen <em>et al.</em> <a href="#ajo13204-bib-0027" data-ref-type="ref"><sup>27</sup></a></td><td>5</td><td>38<sup>+0</sup>–41<sup>+0</sup></td><td>100 (admission)</td><td>100 (postpartum)</td><td>40</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Yu <em>et al.</em> <a href="#ajo13204-bib-0026" data-ref-type="ref"><sup>26</sup></a></td><td>7</td><td>37<sup>+0</sup>–40<sup>+2</sup></td><td> </td><td>86</td><td>14</td><td>14</td><td> </td><td> </td><td> </td><td>14</td><td> </td><td> </td></tr><tr class="odd"><td>Zeng <em>et al.</em> <a href="#ajo13204-bib-0014" data-ref-type="ref"><sup>14</sup></a></td><td>33</td><td><p>3 recorded:</p><p><em>n</em> = 1 40<sup>+0</sup></p><p><em>n</em> = 1 40<sup>+4</sup></p><p><em>n</em> = 1 31<sup>+2</sup></p></td><td> </td><td><p>24 (admission)</p><p>15 (postpartum)</p></td><td>30</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td><em>Liu et al</em>.<a href="#ajo13204-bib-0028" data-ref-type="ref"><sup>28</sup></a></td><td>10</td><td>35<sup>+2</sup>–41<sup>+2</sup></td><td> </td><td>70</td><td>40</td><td> </td><td> </td><td> </td><td> </td><td>10</td><td> </td><td> </td></tr><tr class="odd"><td>Yu <em>et al.</em> <a href="#ajo13204-bib-0029" data-ref-type="ref"><sup>29</sup></a></td><td>2</td><td>‐</td><td> </td><td>50</td><td>50</td><td>50</td><td> </td><td> </td><td> </td><td>50</td><td> </td><td> </td></tr><tr class="even"><td>Li <em>et al.</em> <a href="#ajo13204-bib-0033" data-ref-type="ref"><sup>33</sup></a></td><td>16</td><td>33<sup>+6</sup>–40<sup>+0</sup></td><td> </td><td><p>25 (admission)</p><p>50 (postpartum)</p></td><td>0</td><td>0</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Liu <em>et al.</em> <a href="#ajo13204-bib-0034" data-ref-type="ref"><sup>34</sup></a></td><td>16 (confirmed) (Pregnant)</td><td>22–40<sup>+5</sup></td><td> </td><td><p>100 non‐preg vs 44 preg (<em>P</em> &lt; 0.05)</p><p>31 (postpartum)</p></td><td><p>64 non‐preg</p><p>38 preg</p></td><td><p>0 non‐preg</p><p>13 preg</p></td><td> </td><td> </td><td> </td><td> </td><td><p>14 non‐preg</p><p>19 preg</p></td><td> </td></tr><tr class="even"><td>Cao <em>et al.</em> <a href="#ajo13204-bib-0035" data-ref-type="ref"><sup>35</sup></a></td><td>10</td><td>33<sup>+6</sup>–40<sup>+5</sup></td><td> </td><td><p>20 (admission)</p><p>50 (postpartum)</p></td><td>10</td><td> </td><td>10</td><td> </td><td> </td><td> </td><td>10</td><td> </td></tr><tr class="odd"><td>Wu <em>et al.</em> <a href="#ajo13204-bib-0036" data-ref-type="ref"><sup>36</sup></a></td><td>6</td><td>36<sup>+4</sup>–40<sup>+3</sup></td><td>100 (admission)</td><td>33 (postpartum)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Liu <em>et al.</em> <a href="#ajo13204-bib-0030" data-ref-type="ref"><sup>30</sup></a></td><td>15</td><td>12<sup>+0</sup>–38<sup>+0</sup></td><td> </td><td>87</td><td>60</td><td> </td><td> </td><td>20</td><td> </td><td> </td><td>27</td><td> </td></tr><tr class="odd"><td>Chen <em>et al.</em> <a href="#ajo13204-bib-0031" data-ref-type="ref"><sup>31</sup></a></td><td>3</td><td>3rd trimester</td><td> </td><td>100</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Xu <em>et al</em>.<a href="#ajo13204-bib-0032" data-ref-type="ref"><sup>32</sup></a></td><td>5</td><td>34<sup>+4</sup>–38<sup>+6</sup></td><td> </td><td>100</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Zeng <em>et al.</em> <a href="#ajo13204-bib-0013" data-ref-type="ref"><sup>13</sup></a></td><td>6</td><td>3rd trimester</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="even"><td>Chen <em>et al.</em> <a href="#ajo13204-bib-0037" data-ref-type="ref"><sup>37</sup></a></td><td>9</td><td>36<sup>+0</sup>–39<sup>+4</sup></td><td> </td><td>78</td><td>44</td><td> </td><td> </td><td>33</td><td> </td><td> </td><td> </td><td><p>Sore throat ‐ 22</p><p>Malaise ‐ 22</p></td></tr><tr class="odd"><td>Yang <em>et al.</em> <a href="#ajo13204-bib-0038" data-ref-type="ref"><sup>38</sup></a></td><td>7</td><td>36<sup>+0</sup>–38<sup>+2</sup></td><td> </td><td>71</td><td>14</td><td> </td><td> </td><td> </td><td> </td><td>14</td><td> </td><td>Abdominal pain ‐ 14</td></tr><tr class="even"><td>Liao <em>et al</em>.<a href="#ajo13204-bib-0039" data-ref-type="ref"><sup>39</sup></a></td><td>10</td><td>36<sup>+2</sup>–40<sup>+4</sup></td><td> </td><td>50</td><td>30</td><td> </td><td>10</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Zhu <em>et al</em>.<a href="#ajo13204-bib-0061" data-ref-type="ref"><sup>61</sup></a></td><td>9</td><td>31<sup>+0</sup>–39<sup>+0</sup></td><td> </td><td>78</td><td>40</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Chen <em>et al.</em> <a href="#ajo13204-bib-0081" data-ref-type="ref"><sup>81</sup></a></td><td>84</td><td><p>1st tri: 18.6%</p><p>2nd tri: 17.8%</p><p>3rd tri: 63.6%</p></td><td>5</td><td>78</td><td>73</td><td>10</td><td>24</td><td>7.7</td><td>6.4</td><td>9</td><td>22</td><td><p>Nausea ‐ 5</p><p>Sore throat ‐ 2.6</p><p>Nasal congestion ‐ 2.6</p></td></tr><tr class="odd"><td>Yan <em>et al</em>.<a href="#ajo13204-bib-0052" data-ref-type="ref"><sup>52</sup></a></td><td>65</td><td>5<sup>+0</sup>–41<sup>+2</sup></td><td>9</td><td>69</td><td>43</td><td>17</td><td> </td><td>8</td><td> </td><td>1.5</td><td>20</td><td>Sore throat ‐ 15</td></tr><tr class="even"><td>Huang <em>et al</em>.<a href="#ajo13204-bib-0018" data-ref-type="ref"><sup>18</sup></a></td><td>8</td><td>30<sup>+0</sup>–39<sup>+3</sup></td><td> </td><td>62.5</td><td>87.5</td><td>37.5</td><td> </td><td>37.5</td><td> </td><td> </td><td>37.5</td><td><p>Sputum ‐ 25</p><p>Rhinorrhoea – 37.5</p></td></tr><tr class="odd"><td>Liu <em>et al.</em> <a href="#ajo13204-bib-0051" data-ref-type="ref"><sup>51</sup></a></td><td>13</td><td><p><em>n</em> = 2 &lt;28<sup>+0</sup></p><p><em>n</em> = 11 &gt;28<sup>+0</sup></p></td><td> </td><td>77</td><td> </td><td>23</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Chen et al.<a href="#ajo13204-bib-0082" data-ref-type="ref"><sup>82</sup></a></td><td>4</td><td>37<sup>+2</sup>–39<sup>+0</sup></td><td> </td><td>75</td><td>50</td><td> </td><td> </td><td>50</td><td>50</td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Wu <em>et al.</em> <a href="#ajo13204-bib-0083" data-ref-type="ref"><sup>83</sup></a></td><td>23</td><td>8<sup>+0</sup>–40<sup>+0</sup></td><td>65</td><td>17</td><td>26</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>Nasal congestion ‐ 4</td></tr><tr class="even"><td>Juusela <em>et al.</em> <a href="#ajo13204-bib-0049" data-ref-type="ref"><sup>49</sup></a></td><td>7 (only 2 described in detail)</td><td>33<sup>+6</sup> &amp; 39<sup>+2</sup></td><td> </td><td>100</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td><p>Tachycardia 100</p><p>Tachypnoea 100</p></td></tr><tr class="odd"><td>Li <em>et al</em>.<a href="#ajo13204-bib-0084" data-ref-type="ref"><sup>84</sup></a></td><td>4 (originally positive, negative at time of writing)</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="even"><td>CDC <a href="#ajo13204-bib-0085" data-ref-type="ref"><sup>85</sup></a></td><td>143</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="odd"><td>Blitz <em>et al</em>.<a href="#ajo13204-bib-0086" data-ref-type="ref"><sup>86</sup></a></td><td>82</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="even"><td>Buonsenso <em>et al</em>.<a href="#ajo13204-bib-0054" data-ref-type="ref"><sup>54</sup></a></td><td>7 (only 2 described in detail)</td><td>34<sup>+4</sup> &amp; 37<sup>+3</sup></td><td> </td><td>50</td><td>100</td><td>50</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Chen <em>et al</em>.<a href="#ajo13204-bib-0087" data-ref-type="ref"><sup>87</sup></a></td><td>3</td><td><p><em>n</em> = 1 6</p><p><em>n</em> = 1 25</p><p><em>n</em> = 1 35</p></td><td> </td><td>100</td><td> </td><td>33</td><td>33</td><td> </td><td> </td><td>33</td><td> </td><td> </td></tr><tr class="even"><td>Ferrazzi <em>et al</em>.<a href="#ajo13204-bib-0059" data-ref-type="ref"><sup>59</sup></a></td><td>42</td><td><p><em>n</em> = 30 &gt;37</p><p><em>n</em> = 7 34–37</p><p><em>n</em> = 4 ≤34</p></td><td> </td><td><p>48 (admission)</p><p>14 (postpartum)</p></td><td>43</td><td>19</td><td> </td><td>17</td><td> </td><td>5</td><td> </td><td> </td></tr><tr class="odd"><td>Gagliardi <em>et al</em>.<a href="#ajo13204-bib-0042" data-ref-type="ref"><sup>42</sup></a></td><td>3</td><td>Women admitted for delivery</td><td>67</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>Anosmia – 33</td></tr><tr class="even"><td>Govind <em>et al</em>.<a href="#ajo13204-bib-0056" data-ref-type="ref"><sup>56</sup></a></td><td>9</td><td>27<sup>+0</sup>–39<sup>+0</sup></td><td> </td><td>44</td><td>89</td><td>44</td><td> </td><td>56</td><td> </td><td> </td><td>67</td><td><p>Sore throat – 44</p><p>Anosmia – 78</p></td></tr><tr class="odd"><td>Hantoushzadeh <em>et al</em>.<a href="#ajo13204-bib-0048" data-ref-type="ref"><sup>48</sup></a></td><td>9</td><td>24<sup>+0</sup>–38<sup>+3</sup></td><td> </td><td>100</td><td>100</td><td>67</td><td> </td><td>44</td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Hirshberg <em>et al</em>.<a href="#ajo13204-bib-0053" data-ref-type="ref"><sup>53</sup></a></td><td>5</td><td>25<sup>+2</sup> –31<sup>+2</sup></td><td> </td><td>100</td><td>80</td><td>80</td><td> </td><td> </td><td>20</td><td> </td><td>20</td><td> </td></tr><tr class="odd"><td>Khalil <em>et al</em>.<a href="#ajo13204-bib-0043" data-ref-type="ref"><sup>43</sup></a></td><td>9</td><td>‐</td><td>89</td><td>11</td><td>11</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="even"><td>Penfield <em>et al</em>.<a href="#ajo13204-bib-0057" data-ref-type="ref"><sup>57</sup></a></td><td>32</td><td>26<sup>+5</sup>–41<sup>+0</sup></td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="odd"><td>Pierce‐Williams <em>et al</em>.<a href="#ajo13204-bib-0047" data-ref-type="ref"><sup>47</sup></a></td><td>64</td><td>29 ± 6</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="even"><td>Qiancheng <em>et al</em>.<a href="#ajo13204-bib-0088" data-ref-type="ref"><sup>88</sup></a></td><td>28</td><td>Median 38<sup>+0</sup></td><td> </td><td>18</td><td>25</td><td>7</td><td> </td><td> </td><td> </td><td> </td><td>3.6</td><td>Abdominal pain – 18</td></tr><tr class="odd"><td>Vintzileos <em>et al</em>.<a href="#ajo13204-bib-0044" data-ref-type="ref"><sup>44</sup></a></td><td>32</td><td>‐</td><td>66</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="even"><td>An <em>et al</em>.<a href="#ajo13204-bib-0016" data-ref-type="ref"><sup>16</sup></a></td><td>3</td><td><p><em>n</em> = 1 38<sup>+2</sup></p><p><em>n</em> = 1 39<sup>+4</sup></p><p><em>n</em> = 1 38<sup>+5</sup></p></td><td> </td><td>100</td><td>67</td><td>67</td><td>33</td><td> </td><td> </td><td>33</td><td>33</td><td> </td></tr><tr class="odd"><td>Hu <em>et al</em>.<a href="#ajo13204-bib-0017" data-ref-type="ref"><sup>17</sup></a></td><td>7</td><td>37<sup>+2</sup>–41<sup>+2</sup></td><td>‐</td><td>57</td><td>14</td><td> </td><td>‐</td><td>‐</td><td>‐</td><td> </td><td> </td><td>‐</td></tr><tr class="even"><td>Sun <em>et al</em>.<a href="#ajo13204-bib-0019" data-ref-type="ref"><sup>19</sup></a></td><td>3</td><td><p><em>n</em> = 1 30 + 5</p><p><em>n</em> = 1 36</p><p><em>n</em> = 1 37</p></td><td> </td><td>100</td><td>100</td><td>33</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Cooke <em>et al</em>.<a href="#ajo13204-bib-0058" data-ref-type="ref"><sup>58</sup></a></td><td>2</td><td>28<sup>+4</sup> &amp; 28<sup>+6</sup></td><td> </td><td>100</td><td>100</td><td>50</td><td> </td><td> </td><td> </td><td>50</td><td> </td><td>Vomiting – 50</td></tr><tr class="even"><td>Doria <em>et al</em>.<a href="#ajo13204-bib-0045" data-ref-type="ref"><sup>45</sup></a></td><td>12</td><td>37<sup>+0</sup>–41<sup>+0</sup></td><td>92</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>Lokken <em>et al</em>.<a href="#ajo13204-bib-0060" data-ref-type="ref"><sup>60</sup></a></td><td>46</td><td><p><em>n</em> = 23 3rd tri</p><p><em>n</em> = 20 2nd tri</p><p><em>n</em> = 3 1st tri</p></td><td> </td><td>51</td><td>70</td><td>44</td><td> </td><td>30</td><td>33</td><td>7</td><td>28</td><td><p>Anosmia – 30</p><p>Sore throat – 28</p><p>Nasal congestion – 49</p></td></tr><tr class="even"><td>Savasi <em>et al</em>.<a href="#ajo13204-bib-0050" data-ref-type="ref"><sup>50</sup></a></td><td>77</td><td><p><em>n</em> = 50 3rd tri</p><p><em>n</em> = 13 2nd tri</p><p><em>n</em> = 4 1st tri</p></td><td>16</td><td>54</td><td>66</td><td>25</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr class="odd"><td>London <em>et al</em>.<a href="#ajo13204-bib-0062" data-ref-type="ref"><sup>62</sup></a></td><td>68</td><td><p><em>n</em> = 65 3<sup>rd</sup> tri</p><p><em>n</em> = 1 25<sup>+0</sup></p><p><em>n</em> = 1 26<sup>+0</sup></p><p><em>n</em> = 1 17<sup>+0</sup></p></td><td>32.4</td><td>26</td><td>43</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="even"><td>Miller <em>et al</em>.<a href="#ajo13204-bib-0046" data-ref-type="ref"><sup>46</sup></a></td><td>23</td><td>‐</td><td>43.5</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="odd"><td>Qadri &amp; Mariona<a href="#ajo13204-bib-0063" data-ref-type="ref"><sup>63</sup></a></td><td>16</td><td>22<sup>+0</sup>–40<sup>+3</sup></td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td><td>‐</td></tr><tr class="even"><td>Patane <em>et al</em>.<a href="#ajo13204-bib-0055" data-ref-type="ref"><sup>55</sup></a></td><td>2 described in detail</td><td><p><em>n</em> = 1 37<sup>+6</sup></p><p><em>n</em> = 1 35<sup>+1</sup></p></td><td> </td><td>100</td><td>100</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr></tbody></table>

Unless stated otherwise, all symptoms occurred at presentation. While some studies described suspected positive patients based on chest computed tomography or clinical symptoms, only reverse transcription polymerase chain reaction (rtPCR) positive patients have been included in this table unless otherwise specified. If a parameter was not discussed, this is indicated with a hyphen (‐).
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Maternal and neonatal outcomes {#ajo13204-sec-0010}
------------------------------

Maternal, obstetric and neonatal outcomes of rtPCR confirmed SARS‐CoV‐2 positive pregnant patients are listed in Table [2](#ajo13204-tbl-0002){ref-type="table"}. Of the 13 cohort studies that reported on disease severity, severe COVID‐19 illness (pneumonia requiring oxygen support or non‐invasive ventilation) occurred in 0--18% of patients. Critical disease (defined as progression to acute respiratory distress syndrome, sepsis or acute organ dysfunction) was reported in 0--5% of cases. The exception to this was Pierce‐Williams *et al*.[^47^](#ajo13204-bib-0047){ref-type="ref"} where severe and critical COVID‐19 were, respectively, described in 69% and 31% of cases. A total of 111 severe and 40 critical cases were reported across the 13 cohort studies.

###### 

Pregnancy and neonatal outcomes.

+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Study[†](#ajo13204-note-0005){ref-type="fn"}                       | No. rtPCR SARS‐CoV‐2 positive pregnant patients[‡](#ajo13204-note-0006){ref-type="fn"} | No. participants diagnosed at \<37 weeks gestation | Adverse maternal outcomes (of infection)[§](#ajo13204-note-0007){ref-type="fn"}                                                  | Adverse pregnancy outcomes                                                                                                                                 | Neonatal outcomes (% of live deliveries)                                                                                                                                                             | Delivery method (% of live deliveries)                         | Breastfeeding                                             |
+====================================================================+========================================================================================+====================================================+==================================================================================================================================+============================================================================================================================================================+======================================================================================================================================================================================================+================================================================+===========================================================+
| Breslin *et al.* [^15^](#ajo13204-bib-0015){ref-type="ref"}        | 7                                                                                      | *n* = 5 (71%)                                      | Critical disease (*n* = 2, 28.6%)                                                                                                | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | CS (100%) -- *OI*                                              | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 2                                                                                 |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Breslin *et al.* [^40^](#ajo13204-bib-0040){ref-type="ref"}        | 43                                                                                     | ‐                                                  | Severe disease (*n* = 3, 15%)                                                                                                    | Preterm birth (*n* = 1, 5.6%) due to preterm labour                                                                                                        | NICU admissions (*n* = 3, 15%) RDS (*n* = 1, 2.3%)preterm neonate 34^+0^ (*n* = 1, 2.3%)                                                                                                             | CS (44%) -- *OI*                                               | Yes                                                       |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 18                                                                                |                                                    | Critical disease (*n* = 2, 4.7%)                                                                                                 |                                                                                                                                                            |                                                                                                                                                                                                      | VD (55%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | ICU admission for respiratory failure, septic shock, multiorgan failure (1 discharged & 1 still admitted at time of publication) |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Sutton *et al.* [^12^](#ajo13204-bib-0012){ref-type="ref"}         | 33 Delivery not discussed                                                              | ‐                                                  | ‐                                                                                                                                |                                                                                                                                                            | ‐                                                                                                                                                                                                    | ‐                                                              | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Baergen *et al*.[^41^](#ajo13204-bib-0041){ref-type="ref"}         | 20                                                                                     | *n* = 4 (20%)                                      | Severe disease (*n* = 1, 5%)                                                                                                     | Preterm birth (*n* = 4, 20%) due to pre‐eclampsia n = 2, preterm labour n = 1, unclear n = 1Placental intramural fibrin deposition (*n* = 9, 45%)          |                                                                                                                                                                                                      | VD (75%)                                                       | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 21                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | CS (25%) -- *OI*                                               |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | (1 × twins)                                                                            |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Chen *et al.* [^22^](#ajo13204-bib-0022){ref-type="ref"}           | 17                                                                                     | *n* = 3 (18%)                                      | ‐                                                                                                                                | Preterm birth (18%) reason unclear                                                                                                                         | ‐                                                                                                                                                                                                    | Elective CS (82%)                                              | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | Emergency CS (18%) *OI*                                        |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Fan *et al.* [^21^](#ajo13204-bib-0021){ref-type="ref"}            | 2                                                                                      | *n* = 1 (50%)                                      | ‐                                                                                                                                | Preterm birth (*n* = 1, 50%) due to persistent maternal fever 38.5°C                                                                                       | Fever, abdominal distension day 4 (*n* = 1, 50%)                                                                                                                                                     | CS (100%) -- *C19*                                             | Not permitted                                             |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | Pneumonia (*n* = 1, 50%)                                                                                                                                                                             |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Zhang *et al.* [^20^](#ajo13204-bib-0020){ref-type="ref"}          | 16                                                                                     | ‐                                                  | ‐                                                                                                                                | No difference between pregnant & non‐pregnant group in PROM, meconium stained liquor, GDM, fetal distress, preterm birth                                   | Pneumonia (*n* = 3)                                                                                                                                                                                  | CS (100%) -- *C19*                                             | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 10                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Khan *et al.* [^23^](#ajo13204-bib-0023){ref-type="ref"}           | 17                                                                                     | ‐                                                  | ‐                                                                                                                                | Preterm birth (*n* = 3, 18%) *reason unclear*                                                                                                              | ***n* = 2 SARS‐CoV‐2 positive neonates** *(at birth)*                                                                                                                                                | CS (100%) -- *C19*                                             | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | Pneumonia (*n* = 5, 29%) 1 SARS‐CoV‐2 positive4 SARS‐CoV‐2 negative                                                                                                                                  |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Khan *et al.* [^24^](#ajo13204-bib-0024){ref-type="ref"}           | 3                                                                                      | *n* = 1 (33%)                                      | ‐                                                                                                                                | Preterm birth (*n* = 1, 33%) reason unclear                                                                                                                | ‐                                                                                                                                                                                                    | VD (100%)                                                      | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Lei *et al.* [^25^](#ajo13204-bib-0025){ref-type="ref"}            | 9                                                                                      | ‐                                                  | Severe disease (*n* = 1, 11%)                                                                                                    | Preterm birth (*n* = 2, 50%)PROM (*n* = 1, 11%)Oligohydramnios (*n* = 1, 11%)Growth restriction (*n* = 1, 11%)                                             | ‐                                                                                                                                                                                                    | CS (75%) reason unclear                                        | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 4                                                                                 |                                                    | Critical disease (*n* = 1, 11%)                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (25%)                                                       |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Chen *et al.* [^27^](#ajo13204-bib-0027){ref-type="ref"}           | 5                                                                                      | ‐                                                  | ‐                                                                                                                                | Fetal distress (*n* = 1, 20%)                                                                                                                              | ‐                                                                                                                                                                                                    | Emergency CS (20%) *OI*Elective CS (20%)VD (60%)               | Not permitted                                             |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Yu *et al.* [^26^](#ajo13204-bib-0026){ref-type="ref"}             | 7                                                                                      | ‐                                                  | ‐                                                                                                                                | ‐                                                                                                                                                          | ***n* = 1 SARS‐CoV‐2 positive neonate**(36 h postpartum)                                                                                                                                             | CS (100%) *C19*                                                | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | mild pneumonia                                                                                                                                                                                       |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Zeng *et al.* [^14^](#ajo13204-bib-0014){ref-type="ref"}           | 33                                                                                     | *n* = 1 (3%)                                       | ‐                                                                                                                                | Fetal distress (*n* = 3, 9%)PROM (*n* = 3, 9%)Preterm birth (*n* = 4, 12%) *reason unclear*                                                                | ***n* = 3 SARS‐CoV‐2 positive neonates**(2 days postpartum) Fever (*n* = 2)Pneumonia (n = 3)Preterm birth (31^+2^) (n = 1) -- Apgar 3 & 4 @ 1 & 5 min: resuscitation required, DIC day 12 postpartum | CS (79%) reason unclear                                        | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (21%)                                                       |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| *Liu et al*.[^28^](#ajo13204-bib-0028){ref-type="ref"}             | 10 (confirmed)                                                                         | ‐                                                  | ‐                                                                                                                                |                                                                                                                                                            |                                                                                                                                                                                                      | CS (95%) reason unclear                                        | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (5%)                                                        |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Yu *et al.* [^29^](#ajo13204-bib-0029){ref-type="ref"}             | 2                                                                                      | *n* = 2 (100%)                                     | ‐                                                                                                                                | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | ‐                                                              | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Li *et al.* [^33^](#ajo13204-bib-0033){ref-type="ref"}             | 16 (confirmed)                                                                         | ‐                                                  | ‐                                                                                                                                | Preterm birth (23.5% vs 5% control, *P* \< 0.05) reason unclearLow birth weight (17.6% vs 2.5% control, *P* \< 0.05)PROM (12.5%)Placental abruption (6.3%) | No significant differences in Apgar scores or gestational age at birth between confirmed cases & control (*P*\> 0.05)                                                                                | CS (87.5%) -- *C19*                                            | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (12.5%)                                                     |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Liu *et al.* [^34^](#ajo13204-bib-0034){ref-type="ref"}            | 16 (confirmed)                                                                         | ‐                                                  | ‐                                                                                                                                | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | ‐                                                              | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Cao *et al*.[^35^](#ajo13204-bib-0035){ref-type="ref"}             | 10                                                                                     | *n* = 3 (30%)                                      |                                                                                                                                  | Preterm birth (*n* = 3, 30%) *for OI*                                                                                                                      | ‐                                                                                                                                                                                                    | VD (20%)                                                       | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 11                                                                                |                                                    |                                                                                                                                  | Fetal distress (*n* = 2, 20%)                                                                                                                              |                                                                                                                                                                                                      | Emergency CS (20%) OI -- fetal distress                        |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | *(1 x twins)*                                                                          |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | Elective CS (60%)                                              |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Wu *et al.* [^36^](#ajo13204-bib-0036){ref-type="ref"}             | 6 (confirmed)                                                                          | *n* = 1 (17%)                                      |                                                                                                                                  | PROM (*n* = 2, 33%)Preterm birth (*n* = 1, 17%) *due to PROM*                                                                                              | ‐                                                                                                                                                                                                    | CS (83%) -- *OI*                                               |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (17%)                                                       |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Liu *et al.* [^30^](#ajo13204-bib-0030){ref-type="ref"}            | 15                                                                                     | ‐                                                  | ‐                                                                                                                                | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | CS (90%) *C19*                                                 | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 11                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (10%)                                                       |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Chen *et al.* [^31^](#ajo13204-bib-0031){ref-type="ref"}           | 3                                                                                      | ‐                                                  | ‐                                                                                                                                | Preterm birth (*n* = 1, 33%) due to fetal distress                                                                                                         | NICU admission of preterm neonate (*n* = 1, 33%)                                                                                                                                                     | CS (100%) reason unclear                                       | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Xu *et al*.[^32^](#ajo13204-bib-0032){ref-type="ref"}              | 5                                                                                      | *n* = 2 (40%)                                      |                                                                                                                                  | Preterm birth (*n* = 2, 40%) due to worsening C19                                                                                                          | ‐                                                                                                                                                                                                    | VD (20%)                                                       | Not permitted                                             |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | CS (80%) *n = *3*C19, n = *1*OI*                               |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Zeng *et al.* [^13^](#ajo13204-bib-0013){ref-type="ref"}           | 6                                                                                      | ‐                                                  | ‐                                                                                                                                | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | CS (100%) *C19*                                                | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Chen *et al.* [^37^](#ajo13204-bib-0037){ref-type="ref"}           | 9                                                                                      | *n* = 4 (44%)                                      | ‐                                                                                                                                | PROM (*n* = 2, 22%)Fetal distress (*n* = 1, 11%)Preterm labour (*n* = 4, 44%)                                                                              |                                                                                                                                                                                                      | CS (100%) *n* = 1 C19, *n* = 8 OI (PROM, pre‐eclampsia, Hx CS) | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Yang *et al.* [^38^](#ajo13204-bib-0038){ref-type="ref"}           | 7                                                                                      | *n* = 4 (57%)                                      | ‐                                                                                                                                | Preterm birth (*n* = 4, 57%) reason unclear                                                                                                                | Mild RDS in preterm neonates                                                                                                                                                                         | Elective CS (71.4%) *C19*                                      | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | (*n* = 2, 28.5%)                                                                                                                                                                                     | Emergency CS (28.6%) -- *OI*pre‐eclampsia                      |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Liao *et al*.[^39^](#ajo13204-bib-0039){ref-type="ref"}            | 10                                                                                     | *n* = 1 (10%)                                      | ‐                                                                                                                                | No significant difference in PROM or preterm birth groups (10% SARS‐CoV‐2 positive vs 9.4% negative group, *P*\> 0.05)                                     | ‐                                                                                                                                                                                                    | VD (100%)                                                      | Not permitted for 14 days postpartum                      |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Zhu *et al*.[^61^](#ajo13204-bib-0061){ref-type="ref"}             | 9                                                                                      | ‐                                                  | ‐                                                                                                                                | PROM (33%)Fetal distress (67%)Preterm labour (60%)                                                                                                         | Dyspnoea (*n* = 6, 60%) *n* = 1 neonatal death                                                                                                                                                       | CS (80%) reason unclear                                        | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 10                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            | Postnatal day 9 due to multiorgan failure and DIC                                                                                                                                                    | VD (20%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | (1 x twins)                                                                            |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Chen *et al.* [^81^](#ajo13204-bib-0081){ref-type="ref"}           | 84 (confirmed)                                                                         | ‐                                                  | Severe disease (*n* = 9, 8%)                                                                                                     | Preterm birth (*n* = 18, 21%) reason unclearMiscarriage (*n* = 3, 2.5%)                                                                                    | ‐                                                                                                                                                                                                    | VD (7%)                                                        | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | Critical disease (*n* = 1, 0.8%)                                                                                                 |                                                                                                                                                            |                                                                                                                                                                                                      | CS (93%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | *n = *38 *C19, n = *24*OI*                                     |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Yan *et al*.[^52^](#ajo13204-bib-0052){ref-type="ref"}             | 65 (confirmed)                                                                         | *n* = 34 (52%)                                     | Severe disease (*n* = 6, 9.2%)                                                                                                   | ‐Preterm birth (*n* = 18, 28%) reason unclear‐PPROM (*n* = 3, 6%)‐Fetal distress (*n* = 7, 11%)                                                            | Severe neonatal asphyxia & neonatal death (*n* = 1, 2%)                                                                                                                                              | CS (88%)                                                       | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 50                                                                                |                                                    | Critical disease (*n* = 2, 3%)                                                                                                   |                                                                                                                                                            | NICU admission (*n* = 17, 34%)                                                                                                                                                                       | *n = *19*C19, n = *25*OI*                                      |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (12%)                                                       |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Huang *et al*.[^18^](#ajo13204-bib-0018){ref-type="ref"}           | 8                                                                                      | *n* = 5 (62.5%)                                    | Severe disease (*n* = 2, 25%)                                                                                                    | ‐Preterm birth (*n* = 3, 37.5%) due to PPROM (n = 1), critical C19 (n = 1), unclear (n = 1)‐PROM (*n* = 1, 12.5%)                                          | Severe neonatal asphyxia (*n* = 4, 56%)                                                                                                                                                              | Elective CS (33%)                                              | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 7                                                                                 |                                                    | Critical disease (*n* = 1, 12.5%)                                                                                                |                                                                                                                                                            | Neonatal death (*n* = 2, 28.6%):                                                                                                                                                                     | Emergency CS (50%) *OI*                                        |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | *(1 x twins)*                                                                          |                                                    |                                                                                                                                  |                                                                                                                                                            | 1 at 18 days postpartum due to severe pneumonia, 1 at birth (reason unclear)                                                                                                                         | VD (17%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | NICU admission of preterm neonates (*n* = 3, 43%)                                                                                                                                                    |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Liu *et al.* [^51^](#ajo13204-bib-0051){ref-type="ref"}            | 13                                                                                     | ‐                                                  | Critical disease (*n* = 1, 8%)                                                                                                   | ‐Fetal distress (*n* = 3, 23%)‐PROM (*n* = 1, 8%)‐Stillbirth (*n* = 1, 8%)‐Preterm labour (*n* = 6, 46%)                                                   | ‐                                                                                                                                                                                                    | Elective CS (50%)                                              | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 10                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | Emergency CS (50%) *OI*                                        |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Chen *et al.* [^82^](#ajo13204-bib-0082){ref-type="ref"}           | 4                                                                                      | ‐                                                  | Severe disease (*n* = 1, 25%)                                                                                                    | Decreased fetal movements (25%)                                                                                                                            | TTN (*n* = 1, 25%)                                                                                                                                                                                   | CS (75%) -- *C19*                                              | Not permitted                                             |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (25%)                                                       |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Wu *et al.* [^83^](#ajo13204-bib-0083){ref-type="ref"}             | 23                                                                                     | *n* = 6 (26%)                                      | ‐                                                                                                                                | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | CS (90%) reason unclear                                        | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 21                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (10%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | (1 x twins)                                                                            |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | T -- 3                                                                                 |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Juusela *et al.* [^49^](#ajo13204-bib-0049){ref-type="ref"}        | 2 described in detail                                                                  | *n* = 1 (50%)                                      | Cardiac arrest (*n* = 1, 50%)                                                                                                    | Fetal tachycardia (*n* = 1, 50%)Preterm birth (*n* = 1, 50%) due to worsening C19                                                                          | ‐                                                                                                                                                                                                    | CS (100%) -- *C19*                                             | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | SVT (*n* = 1, 50%)                                                                                                               |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Li *et al*.[^84^](#ajo13204-bib-0084){ref-type="ref"}              | 4 (originally positive, negative at time of writing)                                   | ‐                                                  | Resolution of symptoms and discharged home, 100% still pregnant                                                                  | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | ‐                                                              | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| CDC[^85^](#ajo13204-bib-0085){ref-type="ref"}                      | 143                                                                                    | ‐                                                  | 31 (22%) general admission                                                                                                       | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | ‐                                                              | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | 4 (3%) ICU                                                                                                                       |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | Outcomes unclear                                                                                                                 |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Blitz *et al*.[^86^](#ajo13204-bib-0086){ref-type="ref"}           | 82                                                                                     | ‐                                                  | Severe disease (*n* = 8, 10%)                                                                                                    | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | ‐                                                              | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Buonsenso *et al*.[^54^](#ajo13204-bib-0054){ref-type="ref"}       | 7                                                                                      | *n* = 6 (86%)                                      |                                                                                                                                  | Spontaneous abortion at 8^+0^ (*n* = 1, 14%)                                                                                                               |                                                                                                                                                                                                      | Elective CS (50%)                                              | Formula in hospital, breastfeeding with mask worn at home |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 2                                                                                 |                                                    |                                                                                                                                  | Preterm birth (*n* = 1, 14*%) reason unclear*                                                                                                              |                                                                                                                                                                                                      | Emergency CS (50%) OI                                          |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Chen *et al*.[^87^](#ajo13204-bib-0087){ref-type="ref"}            | 3                                                                                      | *n* = 2 (67%)                                      |                                                                                                                                  | Fetal distress (*n* = 1, 33%)                                                                                                                              |                                                                                                                                                                                                      | Emergency CS (100%)                                            | Formula in hospital, breastfeeding at home                |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 1                                                                                 |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | *OI --*fetal distress                                          |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | T -- 1                                                                                 |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Ferrazzi *et al*.[^59^](#ajo13204-bib-0059){ref-type="ref"}        | 42                                                                                     | *n* = 11 (26%)                                     | Severe disease (*n* = 7, 16%)                                                                                                    | Preterm birth (*n* = 11, 26%) due to worsening maternal C19 symptoms (n = 2), spontaneous labour (n = 9)                                                   | ***n* = 3 SARS‐CoV‐2 positive neonates**(Day 1 postpartum)                                                                                                                                           | Elective CS (43%) *n* = 10 C19, *n* = 8 OI                     | Yes                                                       |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | *‐ n = 4 (9.5%) ICU*admission, details unclear                                                                                   |                                                                                                                                                            | Apgar \< 7 @ 5 min (*n* = 2, 5%)                                                                                                                                                                     | VD (57%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | Preterm neonates (\<34 weeks)                                                                                                                                                                        |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | NICU admission (*n* = 3, 7%)                                                                                                                                                                         |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | *n *= 1 SARS‐CoV‐2 positive                                                                                                                                                                          |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Gagliardi *et al*.[^42^](#ajo13204-bib-0042){ref-type="ref"}       | 3                                                                                      | ‐                                                  |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | ‐                                                              | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Govind *et al*.[^56^](#ajo13204-bib-0056){ref-type="ref"}          | 9                                                                                      | *n* = 2 (22%)                                      | Critical disease (*n* = 1, 11%)                                                                                                  | Preterm birth (*n* = 2, 22%) due to worsening C19                                                                                                          | ***n* = 1 SARS‐CoV‐2 positive neonate** ‐Apgar 5 & 9 @ 1 & 5 min‐Pneumonia                                                                                                                           | Emergency CS (33%) *n* = 2 C19, *n* = 1 OI                     | Not permitted                                             |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | Elective CS (67%) -- *OI*                                      |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (11%)                                                       |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Hantoushzadeh *et al*.[^48^](#ajo13204-bib-0048){ref-type="ref"}   | 9                                                                                      | *n* = 8, (89%)                                     | 100% critical disease                                                                                                            | FDIU (*n* = 5)                                                                                                                                             | Neonatal death (*n* = 2, twins) Postnatal day 3 due to complications of prematurity                                                                                                                  | CS (100% livebirths) *C19*                                     | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 6                                                                                 |                                                    | *n* = 7 maternal death (78%)                                                                                                     | *n* = 2 mothers mechanically ventilated patient in spont. labour, 3 fetuses                                                                                |                                                                                                                                                                                                      | VD *n* = 1 FDIU                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | *(1 x twins)*                                                                          |                                                    | *n* = 1 critical at time of writing (11%)                                                                                        | *n* = 1 acute hypoxaemia, 1 fetus                                                                                                                          |                                                                                                                                                                                                      | CS *n* = 1 FDIU                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | FDIU -- 5                                                                              |                                                    | *n* = 1 recovered (11%)                                                                                                          | *n* = 1 PPROM, 1 fetus                                                                                                                                     |                                                                                                                                                                                                      | *n* = 3 remained *in utero* at time of writing                 |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | *(1 x twins)*                                                                          |                                                    |                                                                                                                                  | Preterm birth (*n* = 3) due to severe C19                                                                                                                  |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  | *n* = 1 28^+0^ (twins)                                                                                                                                     |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  | *n* = 1 30^+5^                                                                                                                                             |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  | *n* = 1 33^+6^                                                                                                                                             |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Hirshberg *et al*.[^53^](#ajo13204-bib-0053){ref-type="ref"}       | 5                                                                                      | *n* = 5 (100%)                                     | 100% critical disease                                                                                                            | Preterm birth (*n* = 3, 60%) due to worsening C19                                                                                                          | Apgar 2 & 4 @ 1 & 5 mins (*n* = 1, 33%)                                                                                                                                                              | Emergency CS (100%) *C19*                                      | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 3                                                                                 |                                                    | *n* = 1 critical at time of writing                                                                                              |                                                                                                                                                            | Preterm 31^+3^                                                                                                                                                                                       |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | *n* = 4 recovered                                                                                                                |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Khalil *et al*.[^43^](#ajo13204-bib-0043){ref-type="ref"}          | 9                                                                                      | ‐                                                  | ‐                                                                                                                                | ‐                                                                                                                                                          |                                                                                                                                                                                                      | ‐                                                              | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Penfield *et al*.[^57^](#ajo13204-bib-0057){ref-type="ref"}        | 11 described in detail                                                                 | *n* = 2 (18%)                                      | Severe disease (*n* = 2, 18%)                                                                                                    | Preterm birth (*n* = 2, 18%) due to worsening C19                                                                                                          | ‐                                                                                                                                                                                                    | CS (36%) reason unclear                                        | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | Critical disease (*n* = 3, 27%)                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (64%)                                                       |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Pierce‐Williams *et al*.[^47^](#ajo13204-bib-0047){ref-type="ref"} | 64                                                                                     | ‐                                                  | Severe disease (*n* = 44, 69%) Critical disease (*n* = 20, 31%)*n = *1 cardiac arrest                                            | Preterm birth (*n* = 29, 88%). due to critical C19 (*n* = 15), unclear (*n* = 14)                                                                          | ***n* = 1 SARS‐CoV‐2 positive neonate**(day 2 postpartum)                                                                                                                                            | CS (75%) -- *C19*                                              | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 33                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            | NICU admission (*n* = 21, 64%) reasons unclear                                                                                                                                                       | VD (25%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | (1 x twins)                                                                            |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Qiancheng *et al*.[^88^](#ajo13204-bib-0088){ref-type="ref"}       | 28                                                                                     | ‐                                                  | No significant difference in disease severity pregnant vs non‐pregnant patients (7% pregnant vs 2% non‐pregnant, *P*\> 0.05)     | Preterm birth (*n* = 1, 4.3%) due to spont. labour                                                                                                         |                                                                                                                                                                                                      | CS (77%) *reason*unclear                                       | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 23                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (23%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | (1 x twins)                                                                            |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | T -- 4                                                                                 |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Vintzileos *et al*.[^44^](#ajo13204-bib-0044){ref-type="ref"}      | 32                                                                                     | ‐                                                  | ‐                                                                                                                                | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | ‐                                                              | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 29                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| An *et al*.[^16^](#ajo13204-bib-0016){ref-type="ref"}              | 3                                                                                      |                                                    | Severe disease (*n* = 3, 100%)                                                                                                   | ‐                                                                                                                                                          | ‐                                                                                                                                                                                                    | CS (100%)                                                      | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | *n = 1 OI, n = 2 unclear*                                      |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Hu *et al*.[^17^](#ajo13204-bib-0017){ref-type="ref"}              | 7                                                                                      |                                                    |                                                                                                                                  | PROM (*n* = 1, 14%)                                                                                                                                        | ***n* = 1 SARS‐CoV‐2 positive neonate**(day 1 postpartum)                                                                                                                                            | Elective CS (86%) *C19*                                        | Not permitted                                             |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (14%) spont. labour                                         |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Sun *et al*.[^19^](#ajo13204-bib-0019){ref-type="ref"}             | 3                                                                                      | *n* = 2 (67%)                                      | Critical disease & maternal death (*n* = 1, 33%)                                                                                 | Preterm birth (*n* = 2, 67%) reason unclear                                                                                                                | ***n* = 1 SARS‐CoV‐2 positive neonate** (day 6 postpartum)                                                                                                                                           | Emergency CS (100%) reason unclear                             | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | NICU admission of preterm neonates (*n* = 2, 67%)                                                                                                                                                    |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Cooke *et al*.[^58^](#ajo13204-bib-0058){ref-type="ref"}           | 2                                                                                      | *n* = 2 (100%)                                     | Critical disease (*n* = 2, 100%)                                                                                                 | Preterm birth at 28^+5^ & 29^+1^ (*n* = 2, 100%) due to C19                                                                                                | *n* = 1 spontaneous bowel perforation day 1 postpartum -- resection & good recovery                                                                                                                  | CS (100%) *C19*                                                | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | *n* = 1 Apgar 1 & 3 @ 1 & 5 min, good recovery                                                                                                                                                       |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Doria *et al*.[^45^](#ajo13204-bib-0045){ref-type="ref"}           | 12                                                                                     | *n* = 2 (17%)                                      |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | VD (40%)                                                       | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 11                                                                                |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | CS (60%) reason unclear                                        |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | (1 x twins)                                                                            |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Lokken *et al*.[^60^](#ajo13204-bib-0060){ref-type="ref"}          | 46                                                                                     | unclear                                            | Severe disease (*n* = 6, 13%)                                                                                                    | Preterm birth (*n* = 1, 12.5%) due to C19                                                                                                                  |                                                                                                                                                                                                      | VD (62.5%)                                                     | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 7                                                                                 |                                                    |                                                                                                                                  | FDIU at 38^+5^ (*n* = 1, 12.5%) reason unclear                                                                                                             |                                                                                                                                                                                                      | CS (37.5%) *n = *1 *OI, n = *2*C19*                            |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | FDIU -- 1                                                                              |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Savasi *et al*.[^50^](#ajo13204-bib-0050){ref-type="ref"}          | 77                                                                                     | Unclear                                            | Severe disease (*n* = 14, 18%)                                                                                                   | Preterm birth (*n* = 12, 21%) due to C19 (*n* = 11), spont. labour (*n* = 1)                                                                               | ***n* = 4 SARS‐CoV‐2 positive neonates**                                                                                                                                                             | VD (61%)                                                       | Yes                                                       |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 57                                                                                |                                                    | Critical disease (*n* = 4, 5%)                                                                                                   |                                                                                                                                                            | *n = *3 day 1 postpartum                                                                                                                                                                             | CS (39%)                                                       |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    | *n = *3 mechanical ventilation,*n = *1 ECMO                                                                                      |                                                                                                                                                            | *n = *1 day 7 postpartum                                                                                                                                                                             |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | NICU admission (*n* = 9, 16%) reason unclear                                                                                                                                                         |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| London *et al*.[^62^](#ajo13204-bib-0062){ref-type="ref"}          | 68                                                                                     | Unclear                                            | Severe disease symptomatic vs asymptomatic at presentation (26.1% symptomatic vs 0% asymptomatic, *P* \< 0.05)                   | Preterm birth significantly associated with symptomatic presentation (27.3% symptomatic vs 0% asymptomatic, *P* \< 0.05)                                   | **‐**                                                                                                                                                                                                | VD (60%)                                                       | ‐                                                         |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | D -- 55                                                                                |                                                    | Severe disease (*n* = 11, 18%)                                                                                                   | Preterm due to C19 (*n* = 8), decreased fetal movements (*n* = 1)                                                                                          |                                                                                                                                                                                                      | CS (40%) reason unclear                                        |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    | M ‐ 1                                                                                  |                                                    | Critical disease (*n* = 1, 1.5%)                                                                                                 | Miscarriage at 17^+0^ (*n* = 1, 1.5%) reason unclear                                                                                                       |                                                                                                                                                                                                      |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Miller *et al*.[^46^](#ajo13204-bib-0046){ref-type="ref"}          | ‐                                                                                      | ‐                                                  | ‐                                                                                                                                |                                                                                                                                                            | **‐**                                                                                                                                                                                                |                                                                | ‐                                                         |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Qadri & Mariona[^63^](#ajo13204-bib-0063){ref-type="ref"}          | 16                                                                                     | Unclear                                            | Severe disease (*n* = 2, 16.5%)                                                                                                  | Preterm birth (*n* = 1, 6%) due to cervical incompetence                                                                                                   | Outcome of preterm neonate unclear                                                                                                                                                                   | VD (66%)                                                       | Yes with facemask & hand washing                          |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      | CS (44%) -- *OI*                                               |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+
| Patane *et al*.[^55^](#ajo13204-bib-0055){ref-type="ref"}          | 2 described in detail                                                                  | *n* = 1, 50%                                       |                                                                                                                                  | Preterm birth (*n* = 1, 50%) due to non‐reassuring fetal status                                                                                            | ***n* = 2 SARS‐CoV‐2 positive neonates**                                                                                                                                                             | VD (50%)                                                       | Yes with facemask & hand washing                          |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | *n = *1 positive at birth                                                                                                                                                                            | CS (50%) -- *OI*                                               |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | *n = *1 day 7 postpartum                                                                                                                                                                             |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            |                                                                                                                                                                                                      |                                                                |                                                           |
|                                                                    |                                                                                        |                                                    |                                                                                                                                  |                                                                                                                                                            | NICU admission of preterm neonate (*n* = 1, 50%)                                                                                                                                                     |                                                                |                                                           |
+--------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------+-----------------------------------------------------------+

Abbreviations: ARDS, acute respiratory distress syndrome; C19, for COVID‐19 symptoms; CS, caesarean section; ECMO, extracorporeal membrane oxygenation; FDIU, fetal death *in utero*; GGO, ground glass opacity; NNP swab, neonatal nasopharyngeal swab; OI, obstetric indication; PROM, premature rupture of membranes; RDS, respiratory distress syndrome; SOB, shortness of breath; SVT, supraventricular tachycardia; TTN, transient tachypnoea of the newborn; VD, vaginal delivery.
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D, live deliveries (where \# is unequal to \# pregnant patients); T, terminations; M, miscarriage. Unless otherwise specified: All neonates are born to SARS‐CoV‐2 positive mothers confirmed by rtPCR; % maternal outcomes based on \# positive pregnant women, \# neonatal outcomes based on \# live deliveries. If a parameter was not discussed, this is indicated with a hyphen (‐). If the outcome was not identified, the cell is blank.

WHO guidelines for categorisation of COVID‐19 disease severity. Severe disease: fever or suspected respiratory infection, plus one of the following: respiratory rate\> 30 breaths/min; severe respiratory distress; or SpO2 ≤ 93% on room air. Critical disease: patients with acute respiratory distress syndrome (ARDS), sepsis or acute organ dysfunction, usually requires mechanical ventilation
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Extrapulmonary complications occurred in some severe and critical patients, including cardiac impairment, renal failure and coagulopathy.[^18^](#ajo13204-bib-0018){ref-type="ref"}, [^40^](#ajo13204-bib-0040){ref-type="ref"}, [^47^](#ajo13204-bib-0047){ref-type="ref"}, [^48^](#ajo13204-bib-0048){ref-type="ref"}, [^49^](#ajo13204-bib-0049){ref-type="ref"}, [^50^](#ajo13204-bib-0050){ref-type="ref"}, [^51^](#ajo13204-bib-0051){ref-type="ref"} Cardiomyopathy with global hypokinesis and moderately reduced ejection fraction on echocardiogram was reported in two patients.[^49^](#ajo13204-bib-0049){ref-type="ref"} Both women underwent emergency caesarean section delivery, and each experienced postpartum complications of cardiac arrest and supraventricular tachycardia, respectively. Another woman also experienced cardiac arrest; this followed extubation after one week of mechanical ventilation.[^47^](#ajo13204-bib-0047){ref-type="ref"} At the time of publication, both women with cardiac arrest remained ventilated in ICU, while the woman with supraventricular tachycardia was still in hospital but stable. There were eight maternal deaths reported secondary to critical COVID‐19.[^19^](#ajo13204-bib-0019){ref-type="ref"}, [^48^](#ajo13204-bib-0048){ref-type="ref"} Seven of the maternal deaths occurred in a single country (Iran) during the surge in cases in March 2020; of note three of the seven deaths involved twin pregnancies.[^48^](#ajo13204-bib-0048){ref-type="ref"} The other critical cases were not revisited in further publications, so the ultimate outcomes of these patients are unclear.

Of the 22 studies that identified and reported outcomes for women diagnosed with COVID‐19 at less than 37 weeks gestation, preterm birth was reported in 10% to 100% of cases (Table [2](#ajo13204-tbl-0002){ref-type="table"}). With the exception of Yan *et al*.[^52^](#ajo13204-bib-0052){ref-type="ref"}, Hirshberg *et al*.[^53^](#ajo13204-bib-0053){ref-type="ref"} and Buonsenso *et al*.,[^54^](#ajo13204-bib-0054){ref-type="ref"} all SARS‐CoV‐2 positive women in these studies who were diagnosed at less than 37 weeks were also delivered preterm. Preterm delivery occurred due to: an obstetric indication (preterm labour, preterm prelabour rupture of membranes, fetal distress),[^36^](#ajo13204-bib-0036){ref-type="ref"}, [^37^](#ajo13204-bib-0037){ref-type="ref"}, [^54^](#ajo13204-bib-0054){ref-type="ref"}, [^55^](#ajo13204-bib-0055){ref-type="ref"} worsening COVID‐19,[^14^](#ajo13204-bib-0014){ref-type="ref"}, [^21^](#ajo13204-bib-0021){ref-type="ref"}, [^32^](#ajo13204-bib-0032){ref-type="ref"}, [^48^](#ajo13204-bib-0048){ref-type="ref"}, [^49^](#ajo13204-bib-0049){ref-type="ref"}, [^53^](#ajo13204-bib-0053){ref-type="ref"}, [^56^](#ajo13204-bib-0056){ref-type="ref"}, [^57^](#ajo13204-bib-0057){ref-type="ref"}, [^58^](#ajo13204-bib-0058){ref-type="ref"} for no reported indication[^19^](#ajo13204-bib-0019){ref-type="ref"}, [^22^](#ajo13204-bib-0022){ref-type="ref"}, [^24^](#ajo13204-bib-0024){ref-type="ref"}, [^38^](#ajo13204-bib-0038){ref-type="ref"}, [^39^](#ajo13204-bib-0039){ref-type="ref"}, [^52^](#ajo13204-bib-0052){ref-type="ref"}, [^59^](#ajo13204-bib-0059){ref-type="ref"} or a combination of these causes.[^18^](#ajo13204-bib-0018){ref-type="ref"}, [^41^](#ajo13204-bib-0041){ref-type="ref"} Three studies compared the rates of preterm birth between rtPCR confirmed SARS‐CoV‐2 positive and negative pregnant women. Both Zhang *et al.* [^20^](#ajo13204-bib-0020){ref-type="ref"} and Liao *et al*.[^39^](#ajo13204-bib-0039){ref-type="ref"} identified no significant difference between groups (Zhang *et al.* [^20^](#ajo13204-bib-0020){ref-type="ref"} 6% SARS‐CoV‐2 positive vs 13% control; Liao *et al.* [^39^](#ajo13204-bib-0039){ref-type="ref"} 10% SARS‐CoV‐2 positive vs 9.4% control, *P *\> 0.05). Conversely, Li *et al.* [^33^](#ajo13204-bib-0033){ref-type="ref"} noted an increased incidence of preterm birth in the SARS‐CoV‐2 positive group (23.5% vs 5% control, *P* \< 0.05). Caesarean section was performed for over 40% of deliveries in all but five studies.[^24^](#ajo13204-bib-0024){ref-type="ref"}, [^39^](#ajo13204-bib-0039){ref-type="ref"}, [^50^](#ajo13204-bib-0050){ref-type="ref"}, [^57^](#ajo13204-bib-0057){ref-type="ref"}, [^60^](#ajo13204-bib-0060){ref-type="ref"}

Nineteen neonates were SARS‐CoV‐2 positive, based on rtPCR of nasopharyngeal swabs. Three of these were febrile, 15 were asymptomatic and one was born at 31^+2^ weeks; he developed disseminated intravascular coagulopathy (DIC) but was recovering at the time of publication. There were no reported deaths of SARS‐CoV‐2 positive neonates. Six neonates had Apgar scores of less than seven at either one or five minutes postpartum. Five of those were preterm while one was term and SARS‐CoV‐2 positive. Six deaths of SARS‐CoV‐2 negative neonates were reported, due to: multiple organ failure and DIC (*n* = 1),[^61^](#ajo13204-bib-0061){ref-type="ref"} preterm birth (*n* = 2),[^48^](#ajo13204-bib-0048){ref-type="ref"} severe neonatal asphyxia (*n* = 1),[^52^](#ajo13204-bib-0052){ref-type="ref"} pneumonia (visualised on chest X‐ray) (*n* = 1)[^18^](#ajo13204-bib-0018){ref-type="ref"} and for unknown reasons (*n* = 1).[^18^](#ajo13204-bib-0018){ref-type="ref"} There were seven reported stillbirths: two for unclear reasons,[^51^](#ajo13204-bib-0051){ref-type="ref"}, [^60^](#ajo13204-bib-0060){ref-type="ref"} three following spontaneous labour in mechanically ventilated patients,[^48^](#ajo13204-bib-0048){ref-type="ref"} one due to acute maternal hypoxaemia necessitating delivery[^48^](#ajo13204-bib-0048){ref-type="ref"} and one due to preterm rupture of membranes.[^48^](#ajo13204-bib-0048){ref-type="ref"} There were five spontaneous miscarriages. Two occurred at 8^+0^ weeks[^54^](#ajo13204-bib-0054){ref-type="ref"} and 17^+0^ weeks,[^62^](#ajo13204-bib-0062){ref-type="ref"} while gestation was not reported for the other three.[^48^](#ajo13204-bib-0048){ref-type="ref"}

The possibility of vertical transmission was assessed with rtPCR of neonatal nasopharyngeal secretions, placenta, cord blood, amniotic fluid and breastmilk (Table [3](#ajo13204-tbl-0003){ref-type="table"}). Nineteen of a total 655 neonatal nasopharyngeal swabs were SARS‐CoV‐2 positive by rtPCR across ten studies. Four placenta samples and one cord blood sample were positive; however, neonatal nasopharygneal swabs in these cases were negative.[^54^](#ajo13204-bib-0054){ref-type="ref"}, [^57^](#ajo13204-bib-0057){ref-type="ref"} Anti‐SARS‐CoV‐2 immunoglobulin M (IgM) and IgG antibodies were elevated in the serum of three neonates.[^13^](#ajo13204-bib-0013){ref-type="ref"}

###### 

Perinatal testing for maternal to fetal transmission

+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Study[†](#ajo13204-note-0009){ref-type="fn"}                       | No. neonates                                                       | Neonatal nasopharyngeal swab rtPCR | Cord blood rtPCR | Amniotic fluid rtPCR                         | Placenta rtPCR                         | Breast milk rtPCR | Neonatal serum[‡](#ajo13204-note-0010){ref-type="fn"} | Other                                            |
+====================================================================+====================================================================+====================================+==================+==============================================+========================================+===================+=======================================================+==================================================+
| Breslin *et al.* [^15^](#ajo13204-bib-0015){ref-type="ref"}        | 2                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Breslin *et al.* [^40^](#ajo13204-bib-0040){ref-type="ref"}        | 18                                                                 | Negative (*n* = 17, 94%)           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | Indeterminate                      |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 1, 6%)                      |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Sutton *et al.* [^12^](#ajo13204-bib-0012){ref-type="ref"}         | ‐                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Baergen *et al.* [^41^](#ajo13204-bib-0041){ref-type="ref"}        | 21                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Chen *et al.* [^22^](#ajo13204-bib-0022){ref-type="ref"}           | 17                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Fan *et al.* [^21^](#ajo13204-bib-0021){ref-type="ref"}            | 2                                                                  | Negative                           | Negative         | Negative                                     | Negative                               | Negative          | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Zhang *et al.* [^20^](#ajo13204-bib-0020){ref-type="ref"}          | 10                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Khan *et al.* [^23^](#ajo13204-bib-0023){ref-type="ref"}           | 17                                                                 | Positive                           | Negative         | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 2, 12%)                     |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Khan *et al.* [^24^](#ajo13204-bib-0024){ref-type="ref"}           | 3                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Lei *et al.* [^25^](#ajo13204-bib-0025){ref-type="ref"}            | 4                                                                  | Negative                           | Negative         | Negative                                     | ‐                                      | Negative          | ‐                                                     | Vaginal secretions: negative                     |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Chen *et al.* [^27^](#ajo13204-bib-0027){ref-type="ref"}           | 5                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Yu *et al.* [^26^](#ajo13204-bib-0026){ref-type="ref"}             | **7**                                                              | Positive                           | Negative         | ‐                                            | Negative                               | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 1, 14%)                     |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Zeng *et al.* [^14^](#ajo13204-bib-0014){ref-type="ref"}           | **33**                                                             | Positive                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 3, 9%)                      |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| *Liu et al*.[^28^](#ajo13204-bib-0028){ref-type="ref"}             | 10                                                                 | Negative                           | Negative         | Negative                                     | ‐                                      | Negative          | ‐                                                     | Neonatal gastric fluid, urine & faeces: negative |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Yu *et al.* [^29^](#ajo13204-bib-0029){ref-type="ref"}             | ‐                                                                  |                                    |                  | Negative                                     |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    |                                    |                  | (*n* = 2, 100%) -- sampled via amniocentesis |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Li *et al.* [^33^](#ajo13204-bib-0033){ref-type="ref"}             | 16 (confirmed)                                                     | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Liu *et al.* [^34^](#ajo13204-bib-0034){ref-type="ref"}            | 6                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Cao *et al.* [^35^](#ajo13204-bib-0035){ref-type="ref"}            | 11 (only 4 neonates tested)                                        | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Wu *et al.* [^36^](#ajo13204-bib-0036){ref-type="ref"}             | 6                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Liu *et al.* [^30^](#ajo13204-bib-0030){ref-type="ref"}            | 11                                                                 | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Chen *et al.* [^31^](#ajo13204-bib-0031){ref-type="ref"}           | 3                                                                  | Negative                           | ‐                | ‐                                            | Negative                               | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Xu *et al*.[^32^](#ajo13204-bib-0032){ref-type="ref"}              | 5                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Zeng *et al.* [^13^](#ajo13204-bib-0013){ref-type="ref"}           | 6                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | Elevated IgG & IgM (*n* = 2, 33%)                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Chen *et al.* [^37^](#ajo13204-bib-0037){ref-type="ref"}           | 9                                                                  | Negative                           | Negative         | Negative                                     | ‐                                      | Negative          | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Yang *et al.* [^38^](#ajo13204-bib-0038){ref-type="ref"}           | 7                                                                  | Negative                           | Negative         | Negative                                     | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Liao *et al*.[^39^](#ajo13204-bib-0039){ref-type="ref"}            | 10                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Zhu *et al*.[^61^](#ajo13204-bib-0061){ref-type="ref"}             | 10                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Chen *et al.* [^81^](#ajo13204-bib-0081){ref-type="ref"}           | 8 neonates                                                         | Negative                           | ‐                | ‐                                            | ‐                                      | Negative          | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    | 3 mothers (breastmilk)                                             |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Yan *et al*.[^52^](#ajo13204-bib-0052){ref-type="ref"}             | 86 -- unclear if from confirmed or suspected SARS‐CoV‐2 + patients | Negative (*n* = 86)                | Negative         | Negative                                     | ‐                                      | Negative          | ‐                                                     | Vaginal secretions -- negative (*n* = 6)         |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    |                                    | (*n* = 10)       | (*n* = 10)                                   |                                        | (*n* = 12)        |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Huang *et al*.[^18^](#ajo13204-bib-0018){ref-type="ref"}           | 7                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    | (1 x twins)                                                        |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Liu *et al.* [^51^](#ajo13204-bib-0051){ref-type="ref"}            | 10                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Chen *et al*.[^82^](#ajo13204-bib-0082){ref-type="ref"}            | 4                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Wu *et al.* [^83^](#ajo13204-bib-0083){ref-type="ref"}             | 20                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Juusela *et al.* [^49^](#ajo13204-bib-0049){ref-type="ref"}        | 2                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Li *et al*.[^84^](#ajo13204-bib-0084){ref-type="ref"}              | 4 (originally positive, negative at time of writing)               | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| CDC[^85^](#ajo13204-bib-0085){ref-type="ref"}                      | ‐                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Blitz *et al*.[^86^](#ajo13204-bib-0086){ref-type="ref"}           | ‐                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Buonsenso *et al.* [^54^](#ajo13204-bib-0054){ref-type="ref"}      | 2                                                                  | Negative                           | Positive         | Negative                                     | Positive                               | Negative          | SARS‐CoV‐2 IgG 'slightly positive'                    |                                                  |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    |                                    | (*n* = 1, 50%)   |                                              | (*n* = 1, 50%)                         |                   | (*n* = 1, 50%)                                        |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Chen *et al*.[^87^](#ajo13204-bib-0087){ref-type="ref"}            | 3                                                                  | Negative                           | Negative         | Negative                                     | Negative                               | Negative          | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Ferrazzi *et al*.[^59^](#ajo13204-bib-0059){ref-type="ref"}        | 42                                                                 | Positive                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 3, 7%)                      |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Gagliardi *et al*.[^42^](#ajo13204-bib-0042){ref-type="ref"}       | 3                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Govind *et al*.[^56^](#ajo13204-bib-0056){ref-type="ref"}          | 9                                                                  | Positive                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 1, 11%)                     |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Hantoushzadeh *et al*.[^48^](#ajo13204-bib-0048){ref-type="ref"}   | 6                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    | (1 x twins)                                                        |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Hirshberg *et al*.[^53^](#ajo13204-bib-0053){ref-type="ref"}       | 3                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Khalil *et al*.[^43^](#ajo13204-bib-0043){ref-type="ref"}          | ‐                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Penfield *et al*.[^57^](#ajo13204-bib-0057){ref-type="ref"}        | 11 described in detail                                             |                                    |                  |                                              | Positive                               |                   |                                                       |                                                  |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    |                                    |                  |                                              | (*n* = 3, 27%)                         |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Pierce‐Williams *et al*.[^47^](#ajo13204-bib-0047){ref-type="ref"} | 33                                                                 | Positive                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 1, 3%)                      |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Qiancheng *et al*.[^88^](#ajo13204-bib-0088){ref-type="ref"}       | 23                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Vintzileos *et al*.[^44^](#ajo13204-bib-0044){ref-type="ref"}      | 29                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| An *et al*.[^16^](#ajo13204-bib-0016){ref-type="ref"}              | 3                                                                  | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Hu *et al*.[^17^](#ajo13204-bib-0017){ref-type="ref"}              | 7                                                                  | Positive                           | ‐                | Negative                                     | ‐                                      | ‐                 | Negative                                              | Urine & faeces -- negative                       |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 1, 14%)                     |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Sun *et al*.[^19^](#ajo13204-bib-0019){ref-type="ref"}             | 3                                                                  | Positive                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 1, 33%)                     |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Cooke *et al*.[^58^](#ajo13204-bib-0058){ref-type="ref"}           | 2                                                                  | Negative                           |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Doria *et al*.[^45^](#ajo13204-bib-0045){ref-type="ref"}           | 11                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    | (1 x twins)                                                        |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Lokken *et al*.[^60^](#ajo13204-bib-0060){ref-type="ref"}          | 7 ‐ only 1 tested                                                  | ‐                                  | ‐                | ‐                                            | Negative (*n* = 1) Post mortem of FDIU | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Savasi *et al*.[^50^](#ajo13204-bib-0050){ref-type="ref"}          | 57                                                                 | Positive                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
|                                                                    |                                                                    |                                    |                  |                                              |                                        |                   |                                                       |                                                  |
|                                                                    |                                                                    | (*n* = 4, 7%)                      |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| London *et al*.[^62^](#ajo13204-bib-0062){ref-type="ref"}          | 55                                                                 | Negative                           |                  |                                              |                                        |                   |                                                       |                                                  |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Miller *et al*.[^46^](#ajo13204-bib-0046){ref-type="ref"}          | ‐                                                                  | ‐                                  | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Qadri & Mariona[^63^](#ajo13204-bib-0063){ref-type="ref"}          | 16                                                                 | Negative                           | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+
| Patane *et al*.[^55^](#ajo13204-bib-0055){ref-type="ref"}          | 2 described in detail                                              | Positive (*n* = 2)                 | ‐                | ‐                                            | ‐                                      | ‐                 | ‐                                                     | ‐                                                |
+--------------------------------------------------------------------+--------------------------------------------------------------------+------------------------------------+------------------+----------------------------------------------+----------------------------------------+-------------------+-------------------------------------------------------+--------------------------------------------------+

All neonates are born to SARS‐CoV‐2 positive mothers confirmed by reverse transcription polymerase chain reaction (rtPCR). Mothers with suspected SARS‐CoV‐2 and their neonates have not been included. If a parameter was not tested, this is indicated with a hyphen (‐).
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All samples tested by rtPCR unless otherwise specified.FDIU, fetal death *in utero*
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SARS‐CoV‐2 was not identified in any of the 45 breastmilk samples tested. Breastfeeding with facemask and hand washing before neonatal contact was permitted in four studies. No neonate tested positive for SARS‐CoV‐2 by nasopharyngeal swab rtPCR in Breslin *et al*.[^40^](#ajo13204-bib-0040){ref-type="ref"} and Qadri and Mariona,[^63^](#ajo13204-bib-0063){ref-type="ref"} while one neonate in Patane *et al*.[^55^](#ajo13204-bib-0055){ref-type="ref"} was SARS‐CoV‐2 positive at birth and hence permitted to breastfeed. One neonate in Savasi *et al*.[^50^](#ajo13204-bib-0050){ref-type="ref"} tested positive at day seven after breastfeeding and rooming in. Breastfeeding was not permitted in seven studies, while no mention of feeding method was made in the remaining papers.

Discussion {#ajo13204-sec-0011}
==========

Our comprehensive review of published case series and cohort studies describing SARS‐CoV‐2 infection in pregnancy has demonstrated a wide variation in symptoms and presentation. While severe illness and adverse maternal outcomes have been described, they appear to approximate rates seen in the non‐pregnant population. Prevalence of preterm birth was elevated in numerous studies; however, those with the highest rates tended to have the smallest participant numbers. Vertical transmission appears possible; however, the occurrence of *in utero* transmission remains unclear.

In the six studies to universally test all pregnant women for SARS‐CoV‐2 infection regardless of symptoms, rates of asymptomatic infection were high (43.5--92%). Two earlier large systematic reviews of non‐pregnant individuals identified fever in 87.3--88.7% and cough in 57.6--58.1% of SARS‐CoV‐2 rtPCR positive patients, indicating that symptomatic presentation is highly typical in the wider population.[^64^](#ajo13204-bib-0064){ref-type="ref"}, [^65^](#ajo13204-bib-0065){ref-type="ref"} Pregnant women require frequent contact with the medical system and the differences observed may represent different approaches to testing. The universal screening approach utilised by the six studies may have resulted in earlier detection of positive pregnant patients before symptom onset, whereas the non‐pregnant population is currently more likely to present only once symptoms emerge. It is also possible that the higher detection rate of asymptomatic pregnant women compared to the general population may be related to age, given that the true prevalence of infection in the broader 20--40‐year‐old population is unknown due to the absence of large‐scale screening measures and the current reliance on symptomatology for testing. Widespread screening in unselected populations will be required to resolve this disparity. A significantly reduced fever incidence in pregnancy compared to non‐pregnant patients was observed by Liu *et al.* [^34^](#ajo13204-bib-0034){ref-type="ref"} This suggests that some symptoms and signs of SARS‐CoV‐2 infection may be modified by pregnancy; however, it must be acknowledged that only 16 pregnant and 14 non‐pregnant rtPCR positive patients were compared.

Unlike for SARS, MERS or influenza, pregnancy does not appear to be associated with an elevated risk of serious maternal COVID‐19 illness compared with the non‐pregnant population. In almost all cohort studies describing disease severity, rates of severe and critical disease approximated those of the general population (14% severe and 5% critical as reported by the World Health Organization[^3^](#ajo13204-bib-0003){ref-type="ref"}). It was therefore noteworthy that Pierce‐Williams *et al.* [^47^](#ajo13204-bib-0047){ref-type="ref"} observed 69% severe and 31% critical disease; however, all study participants were hospital inpatients admitted for COVID‐19, hence selection bias may explain these findings. Ferrazzi *et al.* [^59^](#ajo13204-bib-0059){ref-type="ref"} noted an ICU admission rate of 9.5%; however, it was unclear what the admission criteria for ICU were and whether the women had severe or critical COVID‐19 disease. For clarity, future work must transparently describe the exact nature of clinical features, patient management and adverse outcomes. Maternal mortality may occur in critical cases of COVID‐19. Given that full outcome data for most of the critical patients were not confirmed, the true impact of SARS‐CoV‐2 infection on maternal mortality compared to the general population cannot be reliably ascertained at present.

A broad range of extrapulmonary complications of COVID‐19 have been reported in non‐pregnant patients, including acute cardiac injury and acute kidney injury.[^64^](#ajo13204-bib-0064){ref-type="ref"}, [^65^](#ajo13204-bib-0065){ref-type="ref"} Cardiomyopathy was described in two cases in pregnancy. A study of non‐pregnant patients with COVID‐19 found an elevated risk of cardiomyopathy in those with hypertension, diabetes mellitus or cardiovascular disease.[^66^](#ajo13204-bib-0066){ref-type="ref"} These are the comorbidities most frequently associated with severe and critical COVID‐19.[^67^](#ajo13204-bib-0067){ref-type="ref"} Pregnant patients with cardiometabolic conditions may require additional monitoring if SARS‐CoV‐2 infection occurs during pregnancy.

Prior to the SARS‐CoV‐2 pandemic, a cohort study comparing pregnant women with and without pneumonia reported that preterm birth, low birthweight and fetal growth restriction were significantly more prevalent in women with pneumonia.[^68^](#ajo13204-bib-0068){ref-type="ref"} In the current review, there was a wide variation in the incidence of preterm birth, which contrasts with the 5--18% global incidence in the general pregnant population.[^69^](#ajo13204-bib-0069){ref-type="ref"} The true rate of preterm birth related to SARS‐CoV‐2 infection cannot be determined from studies in this review; small sample size, lack of widespread population screening or matched control groups, insufficient information on the numbers of women diagnosed preterm, and a lack of clear explanation for the causes of preterm birth render it difficult to draw meaningful conclusions. The impact of antenatal infection with COVID‐19 on neonatal outcomes is similarly unclear, and longer‐term follow‐up of infants born to mothers with COVID‐19 is required to assess whether there are any long‐term implications.

Caesarean section was commonly performed for patients with COVID‐19. As such, the incidence of caesarean section in most studies ranged from 40% to 100% -- greater than the Chinese and US averages of 37%[^70^](#ajo13204-bib-0070){ref-type="ref"} and 32%,[^71^](#ajo13204-bib-0071){ref-type="ref"} respectively. Caesarean section was undertaken for obstetric indications or due to uncertainty about maternal to child transmission via vaginal delivery with active infection. While only two studies described 100% vaginal delivery, it is reassuring that no neonates in these cases were SARS‐CoV‐2 positive. Both the International Federation of Gynecology and Obstetrics (FIGO) and the Royal College of Obstetricians and Gynaecologists (RCOG) state that mode of delivery should not be influenced by presence of COVID‐19 (unless urgent delivery is indicated due to severe respiratory compromise).[^72^](#ajo13204-bib-0072){ref-type="ref"}, [^73^](#ajo13204-bib-0073){ref-type="ref"} These recommendations arose after many of the cases reported in this review had delivered.

Nineteen neonates were diagnosed with COVID‐19, raising the possibility of vertical transmission. This contrasts with SARS, where no evidence of vertical transmission exists.[^74^](#ajo13204-bib-0074){ref-type="ref"}, [^75^](#ajo13204-bib-0075){ref-type="ref"} The timing of sampling and contact with the infected mother may be pivotal to ascertaining when this transmission occurred. Only Khan *et al.* [^23^](#ajo13204-bib-0023){ref-type="ref"} and Patane *et al*.[^55^](#ajo13204-bib-0055){ref-type="ref"} took nasopharyngeal swabs immediately following delivery to identify possible *in utero* transmission (caesarean and vaginal delivery, respectively). All others with SARS‐CoV‐2 positive neonates took samples between 24 hours and six days postpartum, so it is possible that infection occurred either prior to, during or after birth. Zeng *et al.* [^13^](#ajo13204-bib-0013){ref-type="ref"} identified elevated serum anti‐SARS‐CoV‐2 IgM in two neonates. Given that IgM antibodies are too large to cross the placenta and serum was sampled immediately postpartum, this again suggests the possibility of *in utero* transmission, although further work in this area is needed given the small numbers to date. In both of these cases the nasopharyngeal swabs were negative. The significance of three positive placenta samples in Penfield *et al*.[^57^](#ajo13204-bib-0057){ref-type="ref"} and one positive placenta and cord blood sample in Buonsenso *et al*.[^54^](#ajo13204-bib-0054){ref-type="ref"} is uncertain given that neonates were SARS‐CoV‐2 negative.

The lack of SARS‐CoV‐2 detection in breastmilk suggests that the virus may not be excreted via this route; however, results of only 45 samples have been reported. Breastfeeding also requires significant maternal‐neonatal contact, which poses risks of contact and droplet transmission. The Centers for Disease Control and Prevention, FIGO and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists recommend that breastfeeding be encouraged for mild and moderate infections, with the application of a surgical mask and careful hand washing before contact.[^72^](#ajo13204-bib-0072){ref-type="ref"}, [^76^](#ajo13204-bib-0076){ref-type="ref"}, [^77^](#ajo13204-bib-0077){ref-type="ref"} In severe infection, expression of breastmilk should be considered where possible. Breastfeeding from birth with the use of surgical mask and hand washing was permitted in four studies.[^40^](#ajo13204-bib-0040){ref-type="ref"}, [^50^](#ajo13204-bib-0050){ref-type="ref"}, [^55^](#ajo13204-bib-0055){ref-type="ref"}, [^63^](#ajo13204-bib-0063){ref-type="ref"} The absence of neonatal COVID‐19 in Breslin *et al*.[^40^](#ajo13204-bib-0040){ref-type="ref"} and Qadri and Mariona[^63^](#ajo13204-bib-0063){ref-type="ref"} supports the guidelines for breastfeeding. The significance of one neonate testing positive for SARS‐CoV‐2 after rooming in and breastfeeding is uncertain.[^50^](#ajo13204-bib-0050){ref-type="ref"}

Our review has some limitations. As per our inclusion criteria even very small case series were included which may result in some clinical features and outcomes to appear amplified. There was substantial heterogeneity between the included studies, particularly in the study type (case series, cohorts or universal screening), clinical management and reporting of outcomes. This may engender considerable bias in the proportions of features identified and limits the comparison between studies. However, our broader inclusion criteria meant that a large number of countries were represented, allowing superior characterisation of the international experience. A meta‐analysis was not possible due to the possibility of individual cases being reported in multiple studies from the same institution. For clarity and enhanced accuracy of datasets, future papers should clearly identify participants who are included in previous publications.

A prospective and comprehensive collection of case details is required to address the currently limited data and to improve management of pregnant patients. It is promising that there are global efforts to collect prospectively harmonised data regarding maternal, perinatal and neonatal outcomes, to better inform clinicians and appropriately manage pregnant patients. These include the US PRIORITY study (ClinicalTrials.gov ID NCT04323839) which has recruited 790 women as of 1 June 2020,[^78^](#ajo13204-bib-0078){ref-type="ref"} the UK Obstetric Surveillance System (UKOSS) study which will soon publish a report of 427 COVID‐19 affected pregnancies[^79^](#ajo13204-bib-0079){ref-type="ref"} and the Australian‐based CHOPAN registry (ANZ Clinical Trials registry ID ACTRN12620000449932).[^80^](#ajo13204-bib-0080){ref-type="ref"}

No study has yet assessed the effect of COVID‐19 in the first trimester on the developing fetus. This data is unlikely to be available until after June 2020 given this novel virus only emerged in December 2019. Given the paucity of data pertaining to the consequences of early and mid‐pregnancy infection, FIGO has recommended monthly ultrasound scans for fetal morphology and growth.[^72^](#ajo13204-bib-0072){ref-type="ref"} It will be of future interest to assess whether infection during this stage of pregnancy predisposes to an increased rate of birth defects or other adverse paediatric and maternal outcomes.

In conclusion, this review has collated the published case series and cohort studies involving pregnant women with SARS‐CoV‐2 infection up until May 23, 2020. This data has demonstrated maternal mortality rates comparable with those in the non‐pregnant population. Rates of preterm birth and caesarean delivery appear high, but it is unclear how much this relates to the clinical course of the disease and how much is iatrogenic. Uncommon but serious complications of infection for both mother and neonate are recognised. Vertical transmission is possible; however, timing of infection (*in utero*, intrapartum or postpartum) and rate of transmission are unclear. A number of questions remain unanswered, and further systematic reviews will be required as more data is accumulated in this rapidly evolving pandemic.
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